For clinicians and researchers alike, SpinTech is an essential MRI technology partner. Through rapid, quantitative brain imaging software, we enable improved diagnosis and treatment of dangerous neurological conditions like stroke, dementia, TBI, Parkinson’s and MS.
Clinicians rely on SpinTech to return better outcomes for patients while improving efficiency and reducing capital expenses. Researchers trust us for the reliable detection and quantification of biomarkers in the development of new treatments and drugs.
Why do we do it?
Neurological disorders reduce quality of life or threaten the lives of over 10 million Americans each year. As a generation of baby boomers is aging, this number is increasing rapidly. Quickly and accurately quantifying neurological biomarkers is critical to proper diagnosis and treatment. For example, detecting microbleeds in TBI or stroke may impact whether a patient is treated properly or not, and iron concentration in deep brain structures has been shown as a key biomarker in diagnosing and treating Parkinson’s. However, current imaging techniques are not capable of identifying and quantifying these biomarkers in a clinically meaningful timeframe and within existing workflows.
We are committed to bringing the future of imaging technology to every patient suffering from neurological disease, offering quantitative image processing previously reserved for only a handful of research institutions. As clinical research using SPIN continues, we see opportunity to expand beyond neuro-imaging, with potential applications in the liver, limbs, kidneys, and perinatal areas.
Our core software leverages three decades of leadership in the field of MRI and over $11M of research and development investment through the technology’s originating company.
Founder E. Mark Haacke, Ph.D is an internationally recognized leader, pioneer and trendsetter in the MRI industry. Dr. Haacke is one of the original inventors of MR Angiography (MRA), the inventor of susceptibility weighted imaging (SWI), and a key developer of quantitative susceptibility mapping (QSM), all of which are active in standard clinical and research settings around the world. SpinTech and its staff have been instrumental in scientifically and clinically proving the importance of cerebral microbleeds (CMB) in dementia and traumatic brain injury (TBI), collectively publishing over 300 papers and receiving over 25,000 citations.
SpinTech was founded in 2017 to bring this research-proven imaging software into major clinical and research markets. Since then, we’ve grown rapidly with strategic partners and research hospitals around the world.
Meet Our Team
Learn more about our leadership team.
Meet our partners from around the world.